Breaking News!

CONVINCE trial results show that high dose haemodiafiltration reduces mortality of kidney dialysis patients. 

The results of the CONVINCE trial were presented at the ERA 2023 meeting in Milan

The results of the CONVINCE trial were presented at the ERA 2023 meeting in Milan

. 

Read more about the CONVINCE trial results

To find out more about the CONVINCE Clinical Trial, please check our Q&A section

End stage kidney disease

End stage kidney disease (ESKD) ranks among the most severe chronic non-communicable diseases with an unmet medical need.

Haemodialysis (HD) treatment is the current standard of care for the vast majority of patients with ESKD. HD is associated with high risks of fatal and non-fatal cardiovascular disease, for infections, hospitalisation and low quality of life.

Improvement required

Improvement in the currently available standard is urgently needed. The CONVINCE study aims to determine the best possible dialysis treatment by comparing high-dose HDF versus conventional high-flux HD treatment by carrying out a prospective randomised controlled clinical trial addressing clinical endpoints, quality of life and a cost-utility analysis. 

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 754803